Home>Topics>Finance>Ceos>James Cornelius

James Cornelius

  1. All
  2. Commentary
  3. Stock Reports
  1. New Morningstar Analyst Report for Bristol-Myers Squibb Company

    Stock Reports

    Thu, 4 Sep 2014

    strong pricing power. In early 2010, Lamberto Andreotti and Charles Bancroft took over Bristol's top posts, replacing James Cornelius as CEO and Jean-Marc Huet as CFO, respectively. While these appointments didn't signify a major shift in Bristol

  2. Bristol Makes Second Bid for Imclone

    Commentary

    Tue, 23 Sep 2008

    confidence in Imclone's rights to pipeline drug candidate 11F8 to follow through with the $70 per share offer. Bristol CEO James Cornelius also intends to ask Imclone shareholders for permission to remove all of the members of Imclone's board and replace them

  3. Mystery Bidder Tops Bristol's Imclone Bud

    Commentary

    Wed, 10 Sep 2008

    In addition, we don't think Bristol is likely to substantially increase its bid above its initial offer; Bristol CEO James Cornelius has experience being on the right side of a bidding war from his days at Guidant, and we don't think the firm's key

  4. New CEO, Collaboration at Bristol

    Commentary

    Thu, 26 Apr 2007

    announced the appointment of a permanent CEO and a collaboration with Pfizer PFE. Our opinion of the company is unchanged. James Cornelius , who has served as interim CEO for the past eight months, was named permanent CEO. He began serving as interim CEO following

  5. Bristol's Board Removes CEO Dolan

    Commentary

    Tue, 12 Sep 2006

    Bristol's best-selling drug Plavix was simply one too many mistakes for Bristol's board to stomach. Board member James Cornelius has been named interim CEO, but we expect Bristol's board will undertake a comprehensive search for a permanent replacement

Content Partners